In Q1 2026, Pacira BioSciences posted year-over-year revenue gains driven by its non-opioid pain management portfolio but missed earnings estimates due to elevated operating costs, including increased stock-based compensation and supply chain pressures [S2][N2]. The company is advancing its gene therapy candidate PCRX-201 and strengthening international commercialization efforts via partnerships like LG Chem, underpinning medium-term growth [S1][S9]. Despite a solid liquidity base and manageable leverage, ongoing legal disputes and competitive risks warrant close monitoring. Upcoming milestones include regulatory filings in Asia-Pacific and pipeline trial readouts [S3][N3].